Skip to main
PTHS

PTHS Stock Forecast & Price Target

PTHS Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pelthos Therapeutics Inc has demonstrated significant growth momentum, with an impressive increase in net revenue projections for 4Q, rising to $16.2 million from $4.5 million, supported by a robust 40% growth in unit prescriptions. The company reported 2,716 prescriptions in 3Q25 and further accelerated its performance in October with 2,189 prescriptions, exceeding the entire third quarter's volume within just seven weeks of 4Q25. Additionally, Pelthos is strategically expanding its sales force from 50 to 64 territory managers, aiming to increase coverage from approximately 8,000 to 10,000 clinicians, positioning itself favorably in a significant underlying market.

Bears say

Pelthos Therapeutics Inc faces a negative outlook due to several critical factors that could adversely affect its financial performance. The potential challenges in securing adequate reimbursement levels and market adoption among specialists may result in revenue growth lagging behind projections, especially if competition from alternative products increases and affects market share. Additionally, risks associated with funding shortages and operational execution deficiencies could hinder strategic initiatives and affect overall commercialization efforts, further exacerbating financial uncertainties.

PTHS has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pelthos Therapeutics Inc (PTHS) Forecast

Analysts have given PTHS a Strong Buy based on their latest research and market trends.

According to 4 analysts, PTHS has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pelthos Therapeutics Inc (PTHS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.